Mohammed M. Aboudeif: The Decision-Making Process for Anticoagulation in Stroke
Mohammed M. Aboudeif, Critical Care Registrar at King AbdulAziz University, shared on LinkedIn:
”Timing is often the most critical factor in neurocritical care, especially when balancing the risk of recurrent ischemia against the threat of hemorrhagic transformation.
Standardizing the transition from acute management to long-term prevention is essential for patient safety and clinical excellence.
This visual guide breaks down the decision-making process for Anticoagulation in Stroke, specifically focusing on the initiation of DOACs in patients with Atrial Fibrillation (AF).
Key Takeaways for the Clinical Team:
- The Acute Phase (0-48h): A universal ‘No’ for anticoagulation.
- The focus remains on stabilization, hydration, and DVT prophylaxis (IPC preferred).
Ischemic Stroke and AF
The 1-3-6-12 Rule remains a vital framework for starting DOACs based on stroke severity:
- Day 1: TIA
- Day 3: Mild (NIHSS <8)
- Day 6: Moderate (NIHSS 8-15)
- Day 12: Severe (NIHSS >15)
Hemorrhagic Stroke: A much more conservative approach.
Restarting anticoagulation is generally deferred for 2–4 weeks and reserved for those with high embolic risk (e.g., mechanical valves), requiring careful reassessment of re-bleeding risk.
Standardized protocols like these reduce clinical variability and improve outcomes in the ICU and beyond.”
Stay updated with Hemostasis Today.
-
May 6, 2026, 14:52Christy Abele: Helping People Craft Stories That Connect and Resonate at CHB Symposium
-
May 6, 2026, 14:46Joe Dawson: Follow-Up on a Patient with a History of an IVC Thrombus
-
May 6, 2026, 14:20Emmanuel J. Favaloro: Highlights of Global Haemostasis Testing in the Latest Issue
-
May 6, 2026, 14:02Abdul Mannan: Anemia in Myelofybrosis – Five Fires Behind One Falling Hb
-
May 6, 2026, 14:00Mona Alfaraj: Advancing Care in Inherited Platelet Disorders at 2nd International Hematology and Hemostasis Conference
-
May 6, 2026, 13:56Mahesan Subramaniam: Why Delayed Cord Clamping Benefits Newborn Health
-
May 6, 2026, 13:44Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
-
May 6, 2026, 13:42Irogue Igbinosa: Rethinking Iron Deficiency in Pregnancy with Intravenous Therapy
-
May 6, 2026, 13:34Manaf Aljishi: Three Posters Presented at the Hematology and Hemostasis Conference 2026